{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:47:08Z","timestamp":1789577228743,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.esmoop.2021.100364","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T18:15:18Z","timestamp":1640801718000},"page":"100364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms"],"prefix":"10.1016","volume":"7","author":[{"given":"T.","family":"Al-Toubah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sommerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Strosberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.esmoop.2021.100364_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100364_bib2","first-page":"471","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"7643","key":"10.1016\/j.esmoop.2021.100364_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2021.100364_bib4","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1038\/ncomms4518","article-title":"Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids","volume":"5","author":"Fernandez-Cuesta","year":"2014","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100364_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000497355","article-title":"The tumor microenvironment in neuroendocrine tumors: biology and therapeutic implications","volume":"109","author":"Cives","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"7457","key":"10.1016\/j.esmoop.2021.100364_bib6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100364_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/bjc.2016.229","article-title":"Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study","volume":"115","author":"Vijayvergia","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2021.100364_bib8","doi-asserted-by":"crossref","unstructured":"Mehnert JM, Rugo HS, O'Neil BH, et\u00a0al. Pembrolizumab for patients with PD-L1\u2013positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study. Paper presented at ESMO 2017 Congress. 2017; Barcelona, Spain.","DOI":"10.1093\/annonc\/mdx368"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2021.100364_bib9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1200\/JCO.2019.37.4_suppl.363","article-title":"Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: results of Part A (pembrolizumab alone)","volume":"37","author":"Mulvey","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100364_bib10","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41416-020-0775-0","article-title":"Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials","volume":"122","author":"Vijayvergia","year":"2020","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100364_bib11","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1158\/1078-0432.CCR-19-3014","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study","volume":"26","author":"Strosberg","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"suppl 8","key":"10.1016\/j.esmoop.2021.100364_bib12","doi-asserted-by":"crossref","first-page":"VIII467","DOI":"10.1093\/annonc\/mdy293.001","volume":"29","author":"Yao","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100364_bib13","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A\u00a0phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.esmoop.2021.100364_bib14","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1158\/1078-0432.CCR-20-0621","article-title":"Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers","volume":"26","author":"Klein","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100364_bib15","unstructured":"Capdevila J, Teule A, Lopez C, al. e. A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: the DUNE trial (GETNE 1601). Paper presented at ESMO Virtual Conference. September 19-21, 2020; Virtual."},{"issue":"8","key":"10.1016\/j.esmoop.2021.100364_bib16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100364_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100364_bib18","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100364_bib19","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921003264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921003264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:52Z","timestamp":1761855952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921003264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2059702921003264"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100364","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100364"}}